OTLK NASDAQ
Iselin, NJ 08830
US
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Lundquist Kevin Mich | A-Award | 500,000 | $0.63 | 2026-09-01 |
| Lundquist Kevin Mich | 0 | — | 2026-09-01 | |
| KENYON LAWRENCE A | P-Purchase | 101,010 | $0.99 | 2026-08-14 |
| KENYON LAWRENCE A | P-Purchase | 101,010 | $1.10 | 2026-08-14 |
| Jahr Robert Charles | P-Purchase | 151,515 | $0.99 | 2026-08-14 |